Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III switch study of ACC007 fixed-dose combination versus Genvoya in virologically suppressed adults with HIV-1
ChiCTR2100051605Phase 3Recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ainuovirine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Participants with HIV RNA greater than or equal to 50 copies/mL. Started Oct 2021; status: recruiting.
02
Drugs
ainuovirinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR2100051605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051605.